The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
about
FVIII inhibitors: pathogenesis and avoidanceThe evolution of comprehensive haemophilia care in the United States: perspectives from the frontline.Current and evolving features in the clinical management of haemophiliaFactor VIII gene variants and inhibitor risk in African American hemophilia A patientsGame, set, match for factor VIII mismatch?Achievements, challenges and unmet needs for haemophilia patients with inhibitors: Report from a symposium in Paris, France on 20 November 2014.Development of inhibitory antibodies to therapeutic factor VIII in severe hemophilia A is associated with microsatellite polymorphisms in the HMOX1 promoter.Genomics of bleeding disorders.Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors.Current management of the hemophilic child: a demanding interlocutor. Quality of life and adequate cost-efficacy analysis.Inhibitors in haemophilia: what have we learned from registries? A systematic review.Genetic risk factors for inhibitors in haemophilia A.Strategies for reducing inhibitor formation in severe haemophilia.The growing number of hemophilia registries: Quantity vs. quality.Violating the theory of single gene-single disorder: inhibitor development in hemophiliaThe role of previously untreated patient studies in understanding the development of FVIII inhibitors.Engineering less immunogenic and antigenic FVIII proteins.Enhanced uptake of blood coagulation factor VIII containing immune complexes by antigen presenting cells.Haemophilia treatment in 2030.Treatment burden, haemostatic strategies and real world inhibitor screening practice in non-severe haemophilia A.Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics.The EPIC study: a lesson to learn.Marginal zone B cells are critical to factor VIII inhibitor formation in mice with hemophilia A.The Fc gamma receptor IIa R131H polymorphism is associated with inhibitor development in severe hemophilia A.IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII.Managing haemophilia for life: 4th Haemophilia Global Summit.Partnering to change the world for people with haemophilia: 6(th) Haemophilia Global Summit, Prague, Czech Republic, 24-26(th) September 2015.In silico calculated affinity of FVIII-derived peptides for HLA class II alleles predicts inhibitor development in haemophilia A patients with missense mutations in the F8 gene.Predictive immunogenicity of Refacto AF.A prevalent CTLA4 missense variant significantly associates with inhibitor development in Argentine patients with severe haemophilia A.Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy.Analyses of the FranceCoag cohort support immunogenicity differences among one plasma-derived and two recombinant factor VIII brands in boys with severe hemophilia A.Risk factors associated with inhibitor development in Chinese patients with haemophilia B.
P2860
Q27027224-B5D716F4-BE13-4DAD-941F-97F9A37F0CA7Q30249256-6E22FC90-A91D-4E42-B074-7D8FBF2C41CEQ33708976-E0D32EA7-E1B0-4AD1-966A-D33CBEA70E11Q35953537-2F4E68C7-69CD-48CD-AE21-2C7817083B9EQ36015787-BD969A5C-BB97-463E-B5EC-732E7C36E019Q37185097-32C4C0E9-5EEA-4D9E-B37F-59311B3BEC5BQ37212741-5CC05C5C-570C-4A53-B408-5B1766DB2875Q38206853-72A7623F-372F-476C-A5C9-1AA18BE7B7F2Q38206855-0DF5A2AD-3FA3-4A93-A471-D23F77EEFED2Q38227605-437EEB00-D0A6-49A8-802A-4229BFDC711CQ38244389-593E1305-271E-4A7A-A958-D6A9410187F6Q38308196-AE458D15-09DE-4FEE-80E9-A336FE29780DQ38308222-DC3AC657-BCCC-48BF-B5A9-920092778335Q38351067-2262A587-E2A5-4B35-A559-DE42D49B2C18Q38397087-E700F944-E64A-4A3B-818E-A56846E7F3CDQ38575475-CF62BE45-AC6A-401A-91CF-F264260F4A62Q38632876-822B35AD-3F6D-4967-8682-D8C501D6DB25Q38792889-E8583060-EAF6-4F83-9FBF-FBD03834235BQ38842671-0CC9E3D8-BEB1-4BDF-A0BC-567C74676A3EQ38960476-BF134D78-1C4F-46D6-B322-4ABB39C75586Q39174749-93EAA041-F44C-437C-A85A-B106B1CE5848Q41014168-1A3799F7-66A1-4DD9-8F1A-BFD9D6B0C5E2Q41924275-28371BEC-D7C0-4731-9A57-169E2159A750Q42211106-55AEE7FC-EF59-4DC5-9150-2A2A47DEEC59Q43218590-FB8F9147-7222-4971-B2B5-C2680F2FADF2Q44122887-DEAB2EE3-B758-42FE-99A1-51FE44FA893BQ45855101-52E40857-1CBA-4C4D-B2D3-3114C7FB130FQ45857166-56DBC818-4AD3-4A1E-A316-C5BA4508812DQ45861147-7B9F9DA3-9AD8-4DBE-A055-5CDD2A9942D9Q45864974-577B8A50-34C4-410A-BCAF-360B851A77F9Q45865165-E97CA0BD-75D0-41B5-9BB8-84CCC67FFC3EQ45873084-B1844D22-E807-455F-A649-005B3A0A1106Q45875494-E7C3729D-DE7F-431E-8F9B-808A0DD55C7F
P2860
The polygenic nature of inhibitors in hemophilia A: results from the Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort.
description
2012 nî lūn-bûn
@nan
2012年の論文
@ja
2012年論文
@yue
2012年論文
@zh-hant
2012年論文
@zh-hk
2012年論文
@zh-mo
2012年論文
@zh-tw
2012年论文
@wuu
2012年论文
@zh
2012年论文
@zh-cn
name
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@ast
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@en
type
label
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@ast
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@en
prefLabel
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@ast
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@en
P2093
P2860
P1433
P1476
The polygenic nature of inhibi ...... Study (HIGS) Combined Cohort.
@en
P2093
Amy D Shapiro
Anna Pavlova
Bailey Kessing
Cheryl A Winkler
Donna M DiMichele
Edward D Gomperts
Erik Berntorp
Erika D Menius
Hemophilia Inhibitor Genetics Study (HIGS) Combined Cohort
Jan Astermark
P2860
P304
P356
10.1182/BLOOD-2012-06-434803
P407
P577
2012-12-06T00:00:00Z